[Uterine cervix dysplasias. New therapeutic strategy based on virological data].
There is no consistency in the treatment of dysplasias of the cervix of the uterus. It varies from team to team and there is no criterion that points with any certainty to how the lesion will develop--whether it will become worse, whether it will persist as it is or whether it will regress. For the first time there is an objective factor, namely typing of the papillomavirus by molecular hybridisation. The presence of HPV 16, 18 or 33 is prognostically bad. Active treatment should be instituted. In the other cases "armed surveillance" or destroying the lesions is sufficient. This is particularly important in young women who wish to have a family.